New Drugs

Question 1

Glofitamab

Answer 1

Columvi, Genentech

bispecific CD20-directed CD3 T-cell engager

Indx: R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Question 2

Mosunetuzumab

Answer 2

Lunsumio, Genentech

bispecific CD20-directed CD3 T-cell engager

Indx: R/R Follicular Lymphoma (FL)

Question 3

Epcoritamab

Answer 3

Epkinly, Genmab/Abbvie

bispecific CD20-directed CD3 T-cell engager

relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Question 4

Mirvetuximab

Answer 4

mirvetuximab soravtansine-gynx

Elahere, ImmunoGen

antibody-drug conjugate (ADC) consisting of a monoclonal antibody against FRα (folate receptor⁠–⁠alpha)

Indx: folate receptor⁠–⁠alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

Question 5

Tazverik

Answer 5

Tazemetostat

EZH2 inhibitor, oral

relapsed or refractory (R/R) follicular lymphoma (FL)

Question 6

copanlisib

Answer 6

ALIQOPA, Bayer

IV pan-class I phosphoinositide 3-kinase (PI3K) inhibitor

relapsed follicular lymphoma

Question 7

Infigratinib

Answer 7

Truseltiq, QED Therapeutics,

Oral Kinase Inhibitor of FGFR2

unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

Question 8

Pemigatinib

Answer 8

PEMAZYRE, Incyte Corporation

Oral Kinase Inhibitor of FGFR2

unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

Question 9

Erdafitinib

Answer 9

BALVERSA, Janssen

Oral FGFR inhibitor

locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations